{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:14:31Z","timestamp":1787030071119,"version":"build-2736575974"},"reference-count":54,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RC-2022-2773377"],"award-info":[{"award-number":["RC-2022-2773377"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that promotes tumor cell growth and is implicated in the pathogenesis of human breast cancer. The role of HER2 in canine mammary carcinomas (CMCs) is not clear. Therefore, this study aimed to examine the protein expression and cytogenetic changes of HER2 and their correlation with other clinical\u2013pathological parameters in CMC. We retrospectively selected 112 CMCs. HER2, ER, and Ki67 were assessed by immunohistochemistry. HER2 antibody validation was investigated by immunoblot on mammary tumor cell lines. Fluorescence in situ hybridization (FISH) was performed with probes for HER2 and CRYBA1 (control gene present on CFA9). HER2 protein overexpression was detected in 15 carcinomas (13.5%). A total of 90 carcinomas were considered technically adequate by FISH, and 8 out of 90 CMC (10%) were HER2 amplified, 3 of which showed a cluster-type pattern. HER2 overexpression was correlated with an increased number of HER2 gene copies (p = 0.01; R = 0.24) and overall survival (p = 0.03), but no correlation with ER, Ki67, grade, metastases, and tumor-specific survival was found. Surprisingly, co-amplification or polysomy was identified in three tumors, characterized by an increased copy number of both HER2 and CRYBA1. A morphological translocation-fusion pattern was recognized in 20 carcinomas (22%), with a co-localized signal of HER2 and CRYBA1. HER2 is not associated with clinical\u2013pathological parameters of increased malignancy in canine mammary tumors, but it is suitable for studying different amplification patterns.<\/jats:p>","DOI":"10.3390\/vetsci9110583","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T11:53:55Z","timestamp":1666612435000},"page":"583","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4653-0624","authenticated-orcid":false,"given":"L. V.","family":"Muscatello","sequence":"first","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell\u2019Emilia, 40064 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4082-4675","authenticated-orcid":false,"given":"F.","family":"Gobbo","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell\u2019Emilia, 40064 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Di Oto","sequence":"additional","affiliation":[{"name":"OACP IE Ltd., T12H1XY Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-3484","authenticated-orcid":false,"given":"G.","family":"Sarli","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell\u2019Emilia, 40064 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"De Maria","sequence":"additional","affiliation":[{"name":"Department of Veterinary Sciences, University of Turin, 10095 Grugliasco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-5135","authenticated-orcid":false,"given":"A.","family":"De Leo","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy"},{"name":"Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0113-6682","authenticated-orcid":false,"given":"G.","family":"Tallini","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy"},{"name":"Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2694-905X","authenticated-orcid":false,"given":"B.","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell\u2019Emilia, 40064 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41921","DOI":"10.1038\/srep41921","article-title":"Palindromic Amplification of the ERBB2 Oncogene in Primary HER2-Positive Breast Tumors","volume":"7","author":"Marotta","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_2","unstructured":"(2019). Invasive breast carcinoma: General overview. Breast Tumours, International Agency for Research on Cancer."},{"key":"ref_3","unstructured":"Kumar, V., Abbas, A., and Aster, J. (2021). The Breast. Robbins and Cotran Pathological Basis of Desease, Elsevier Inc."},{"key":"ref_4","first-page":"743193","article-title":"The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy","volume":"2012","author":"Mitri","year":"2012","journal-title":"Chemother. Res. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-019-0436-3","article-title":"The Clinical and Biological Significance of HER2 Over-Expression in Breast Ductal Carcinoma in Situ: A Large Study from a Single Institution","volume":"120","author":"Miligy","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted Therapies\u2014A Role beyond Breast Cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1939-1676.2012.01014.x","article-title":"CA15.3, CEA and LDH in Dogs with Malignant Mammary Tumors","volume":"26","author":"Campos","year":"2012","journal-title":"J. Vet. Intern. Med."},{"key":"ref_11","first-page":"1443","article-title":"Fatores de Progn\u00f3stico Em Carcinomas Mam\u00e1rios Caninos e Sua Rela\u00e7\u00e3o Com Express\u00e3o de HER2","volume":"45","author":"Soares","year":"2017","journal-title":"Acta Sci. Vet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.rvsc.2012.09.016","article-title":"HER-2 Expression in Canine Morphologically Normal, Hyperplastic and Neoplastic Mammary Tissues and Its Correlation with the Clinical Outcome","volume":"94","author":"Ressel","year":"2013","journal-title":"Res. Vet. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tvjl.2007.10.013","article-title":"Increased Survival in Dogs with Malignant Mammary Tumours Overexpressing HER-2 Protein and Detection of a Silent Single Nucleotide Polymorphism in the Canine HER-2 Gene","volume":"180","author":"Hsu","year":"2009","journal-title":"Vet. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1590\/S0100-879X2004001100013","article-title":"C-ErbB-2 Expression and Nuclear Pleomorphism in Canine Mammary Tumors","volume":"37","author":"Dutra","year":"2004","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.7314\/APJCP.2012.13.12.6415","article-title":"Overexpression of Her-2\/Neu in Malignant Mammary Tumors; Translation of Clinicopathological Features from Dog to Human","volume":"13","author":"Muhammadnejad","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Beha, G., Brunetti, B., Asproni, P., Muscatello, L.V., Millanta, F., Poli, A., Sarli, G., and Benazzi, C. (2012). Molecular Portrait-Based Correlation between Primary Canine Mammary Tumor and Its Lymph Node Metastasis: Possible Prognostic-Predictive Models and\/or Stronghold for Specific Treatments?. BMC Vet. Res., 8.","DOI":"10.1186\/1746-6148-8-219"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/vco.12345","article-title":"Overexpression of HER-2 via Immunohistochemistry in Canine Urinary Bladder Transitional Cell Carcinoma\u2014A Marker of Malignancy and Possible Therapeutic Target","volume":"16","author":"Millanta","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e02004","DOI":"10.1016\/j.heliyon.2019.e02004","article-title":"Immunohistochemical Evaluation of HER2 Expression in Canine Thyroid Carcinoma","volume":"5","author":"Yoshimoto","year":"2019","journal-title":"Heliyon"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1292\/jvms.19-0019","article-title":"Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Canine Anal Sac Gland Carcinoma","volume":"81","author":"Yoshimoto","year":"2019","journal-title":"J. Vet. Med. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0300985818817024","article-title":"Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder","volume":"56","author":"Tsuboi","year":"2019","journal-title":"Vet. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0300985819879445","article-title":"ErbB2 Copy Number Aberration in Canine Urothelial Carcinoma Detected by a Digital Polymerase Chain Reaction Assay","volume":"57","author":"Sakai","year":"2020","journal-title":"Vet. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1292\/jvms.20-0026","article-title":"Overexpression of Human Epidermal Growth Factor Receptor 2 in Canine Primary Lung Cancer","volume":"82","author":"Yoshimoto","year":"2020","journal-title":"J. Vet. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Brunetti, B., Bacci, B., Sarli, G., Pancioni, E., and Muscatello, L.V. (2021). Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study. Animals, 11.","DOI":"10.3390\/ani11041006"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1023\/A:1024929730165","article-title":"Oncogene HER-2 in Canine Mammary Gland Carcinomas: An Immunohistochemical and Chromogenic in Situ Hybridization Study","volume":"80","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_25","unstructured":"Zappulli, V. (2019). Mammary Tumors, Davis-Thompson DVM Foundation."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/0300985812447830","article-title":"Prognostic Value of Histological Grading in Noninflammatory Canine Mammary Carcinomas in a Prospective Study with Two-Year Follow-up: Relationship with Clinical and Histological Characteristics","volume":"50","author":"Clemente","year":"2013","journal-title":"Vet. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.rvsc.2011.06.012","article-title":"Establishment of a Pair of Novel Cloned Tumour Cell Lines with or without Metastatic Potential from Canine Mammary Adenocarcinoma","volume":"93","author":"Murai","year":"2012","journal-title":"Res. Vet. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/0300985820973462","article-title":"P53, ER, and Ki67 Expression in Canine Mammary Carcinomas and Correlation With Pathological Variables and Prognosis","volume":"58","author":"Brunetti","year":"2021","journal-title":"Vet. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/0300985818808531","article-title":"HER2 Amplification Status in Feline Mammary Carcinoma: A Tissue Microarray-Fluorescence In Situ Hydridization-Based Study","volume":"56","author":"Muscatello","year":"2019","journal-title":"Vet. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0300985813509388","article-title":"Canine Mammary Tumors: A Review and Consensus of Standard Guidelines on Epithelial and Myoepithelial Phenotype Markers, HER2, and Hormone Receptor Assessment Using Immunohistochemistry","volume":"51","author":"Gama","year":"2014","journal-title":"Vet. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0300985820988147","article-title":"HER2 Overexpression and Amplification in Feline Pulmonary Carcinoma","volume":"58","author":"Muscatello","year":"2021","journal-title":"Vet. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/0300985817698208","article-title":"Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases","volume":"54","author":"Rasotto","year":"2017","journal-title":"Vet. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10549-017-4548-2","article-title":"Canine Invasive Mammary Carcinomas as Models of Human Breast Cancer. Part 1: Natural History and Prognostic Factors","volume":"167","author":"Nguyen","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 Years\u2019 Follow-up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer: Final Analysis of the HERceptin Adjuvant (HERA) Trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.breast.2018.03.006","article-title":"HER2-Positive Breast Cancer: Current and New Therapeutic Strategies","volume":"39","author":"Bellet","year":"2018","journal-title":"Breast"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5306\/wjco.v2.i2.125","article-title":"Current Status of Therapy for Breast Cancer Worldwide and in Japan","volume":"2","author":"Park","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12282-018-0861-9","article-title":"HER2 Genomic Amplification in Circulating Tumor DNA and Estrogen Receptor Positivity Predict Primary Resistance to Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Metastatic Breast Cancer","volume":"25","author":"Sakai","year":"2018","journal-title":"Breast Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"L\u00fcder Ripoli, F., Mohr, A., Conradine Hammer, S., Willenbrock, S., Hewicker-Trautwein, M., Hennecke, S., Murua Escobar, H., and Nolte, I. (2016). A Comparison of Fresh Frozen vs. Formalin-Fixed, Paraffin-Embedded Specimens of Canine Mammary Tumors via Branched-DNA Assay. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050724"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4142\/jvs.2017.18.2.149","article-title":"Estrogen Receptor-\u03b1, Progesterone Receptor, and c-ErbB\/HER-Family Receptor MRNA Detection and Phenotype Analysis in Spontaneous Canine Models of Breast Cancer","volume":"18","author":"Kabir","year":"2017","journal-title":"J. Vet. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-017-4542-8","article-title":"Canine Invasive Mammary Carcinomas as Models of Human Breast Cancer. Part 2: Immunophenotypes and Prognostic Significance","volume":"167","author":"Abadie","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tvjl.2010.08.012","article-title":"Expression of HER-2 and Nuclear Localization of HER-3 Protein in Canine Mammary Tumors: Histopathological and Immunohistochemical Study","volume":"189","author":"Kim","year":"2011","journal-title":"Vet. J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Levi, M., Muscatello, L.V., Brunetti, B., Benazzi, C., Parenti, F., Gobbo, F., Avallone, G., Bacci, B., Zambon, E., and Valenti, P. (2021). High Intrinsic Expression of P-Glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Carcinomas Regardless of Immunophenotype and Outcome. Animals, 11.","DOI":"10.3390\/ani11030658"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1007\/s13277-015-3661-2","article-title":"Investigation of HER2 Expression in Canine Mammary Tumors by Antibody-Based, Transcriptomic and Mass Spectrometry Analysis: Is the Dog a Suitable Animal Model for Human Breast Cancer?","volume":"36","author":"Burrai","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0300985813505879","article-title":"When Tissue Antigens and Antibodies Get along: Revisiting the Technical Aspects of Immunohistochemistry--the Red, Brown, and Blue Technique","volume":"51","author":"Miller","year":"2014","journal-title":"Vet. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0300985813476067","article-title":"Immunohistochemical Evaluation of the Effects of Paraffin Section Storage on Biomarker Stability","volume":"51","author":"Webster","year":"2014","journal-title":"Vet. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1309\/AJCP99WZGBPKCXOQ","article-title":"Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2\/Neu Immunohistochemical and Fluorescence in Situ Hybridization Results in Breast Cancer","volume":"136","author":"Moatamed","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00428-008-0644-3","article-title":"Identification of Molecular Phenotypes in Canine Mammary Carcinomas with Clinical Implications: Application of the Human Classification","volume":"453","author":"Gama","year":"2008","journal-title":"Virchows Arch."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Damasceno, K.A., Ferreira, E., Estrela-Lima, A., Gamba, C.d.O., Miranda, F.F., Alves, M.R., Rocha, R.M., de Barros, A.L.B., and Cassali, G.D. (2016). HER-2 and EGFR MRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland. PLoS ONE., 11.","DOI":"10.1371\/journal.pone.0160419"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/1040638715592445","article-title":"Prognostic Significance of Tissue and Serum HER2 and MUC1 in Canine Mammary Cancer","volume":"27","author":"Campos","year":"2015","journal-title":"J. Vet. Diagn. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/ajcp\/aqy136","article-title":"Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy","volume":"151","author":"Nitta","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1038\/onc.2008.113","article-title":"Unbalanced Translocation, a Major Chromosome Alteration Causing Loss of Heterozygosity in Human Lung Cancer","volume":"27","author":"Ogiwara","year":"2008","journal-title":"Oncogene"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mukherjee, K., and Storici, F. (2012). A Mechanism of Gene Amplification Driven by Small DNA Fragments. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1003119"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ng1215","article-title":"Chromosome Aberrations in Solid Tumors","volume":"34","author":"Albertson","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ng1416","article-title":"Detection of Large-Scale Variation in the Human Genome","volume":"36","author":"Iafrate","year":"2004","journal-title":"Nat. Genet."}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/9\/11\/583\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:00:58Z","timestamp":1760144458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/9\/11\/583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["vetsci9110583"],"URL":"https:\/\/doi.org\/10.3390\/vetsci9110583","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,22]]}}}